Celcuity Inc. (CELC)
Data as of , from SEC Form 4 filings.
See up to 3 months of CELC. The 7-day demo opens the 1M and 3M ranges and puts CELC on your watchlist.
Start 7-day demoLatest CELC insider trades
About Celcuity Inc. (CELC)
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
- MINNEAPOLIS, MN
- 155
- 2017
- XNAS
CELC Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 3,100,000 | $317.75M |
| Grant or award | 7 | 256,893 | |
| Option exercise | 2 | 500 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
CELC insider transactions (Form 4)
6237 Form 4 filings on record, the earliest from Oct 25, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Leo Furcht - Director | Option exercise | Common Stock | 250 | $7.60 | $2K | |
| Leo Furcht - Director | Option exercise | Stock Option (right to buy) | 250 | $0.00 | - | |
| David W. Gryska - Director | Grant or award | Common Stock | 893 footnote F1 | $0.00 | - | |
| ||||||
| Lance G. Laing - Officer | Grant or award | Common Stock | 20,000 footnote F1 | $0.00 | - | |
| Lance G. Laing - Officer | Grant or award | Performance Stock Units | 10,000 | $0.00 | - | |
| ||||||
| Brian F. Sullivan - Officer | Grant or award | Common Stock | 80,000 footnote F1 | $0.00 | - | |
| Brian F. Sullivan - Officer | Grant or award | Performance Stock Units | 120,000 | $0.00 | - | |
| ||||||
| Vicky Hahne - Officer | Grant or award | Common Stock | 16,000 footnote F1 | $0.00 | - | |
| Vicky Hahne - Officer | Grant or award | Performance Stock Units | 10,000 | $0.00 | - | |
| ||||||
| BAKER BROS. ADVISORS LP | Open-market sale | Common Stock | 261,368 | $102.50 | $26.79M | |
| BAKER BROS. ADVISORS LP | Open-market sale | Common Stock | 2,838,632 | $102.50 | $290.96M | |
 Polly A. Murphy | Gift | Stock Option (right to buy) | 14,048 | $0.00 | - | |
| Polly A. Murphy | Gift | Stock Option (right to buy) | 14,048 | $0.00 | - | |
| Richard E. Buller | Gift | Stock Option (right to buy) | 12,503 | $0.00 | - | |
| Richard E. Buller | Gift | Stock Option (right to buy) | 12,503 | $0.00 | - | |
| Polly A. Murphy | Grant or award | Common Stock | 1,530 footnote F1 | $0.00 | - | |
| ||||||
 David Dalvey | Grant or award | Common Stock | 1,530 footnote F1 | $0.00 | - | |
| ||||||
| Charles R. Romp | Grant or award | Common Stock | 1,530 footnote F1 | $0.00 | - | |
| ||||||
| Richard Nigon | Grant or award | Common Stock | 1,530 footnote F1 | $0.00 | - | |
| ||||||
| Leo Furcht | Grant or award | Common Stock | 1,530 footnote F1 | $0.00 | - | |
| ||||||
| Richard E. Buller | Grant or award | Common Stock | 1,530 footnote F1 | $0.00 | - | |
| ||||||
| Lance G. Laing - Officer | Option exercise | Common Stock | 1,000 | $9.89 | $10K | |
| Lance G. Laing - Officer | Option exercise | Stock Option (right to buy) | 1,000 | $0.00 | - | |
| Richard E. Buller | Gift | Common Stock | 1,029 | $0.00 | - | |
| Richard E. Buller | Gift | Common Stock | 1,029 | $0.00 | - | |
| David Dalvey | Open-market sale | Common Stock | 25,000 | $140.68 | $3.52M | |
| Richard E. Buller | Option exercise | Common Stock | 9,000 | $5.10 | $46K | |
| Richard E. Buller | Open-market sale | Common Stock | 1,289 | $137.00 | $177K | |
| Richard E. Buller | Open-market sale | Common Stock | 550 | $139.00 footnote F3 | $76K | |
| Richard E. Buller | Open-market sale | Common Stock | 1,670 | $139.58 footnote F4 | $233K | |
| Richard E. Buller | Open-market sale | Common Stock | 2,301 | $141.03 footnote F5 | $325K | |
| Richard E. Buller | Open-market sale | Common Stock | 2,825 | $142.04 footnote F6 | $401K | |
| Richard E. Buller | Open-market sale | Common Stock | 365 | $143.24 footnote F7 | $52K | |
| Richard E. Buller | Option exercise | Stock Option (right to buy) | 9,000 | $0.00 | - | |
| ||||||
| Richard Nigon | Gift | Common Stock | 10,000 | $0.00 | - | |
| Richard E. Buller | Option exercise | Common Stock | 3,000 | $5.10 | $15K | |
| Richard E. Buller | Open-market sale | Common Stock | 2,325 | $110.11 footnote F3 | $256K | |
| Richard E. Buller | Open-market sale | Common Stock | 675 | $110.83 footnote F4 | $75K | |
| Richard E. Buller | Option exercise | Stock Option (right to buy) | 3,000 | $0.00 | - | |
| ||||||
| Charles R. Romp | Grant or award | Common Stock | 215 footnote F1 | $0.00 | - | |
| ||||||
| David Dalvey | Open-market sale | Common Stock | 20,000 | $120.03 footnote F2 | $2.40M | |
| ||||||
| Richard Nigon | Gift | Common Stock | 19,975 | $0.00 | - | |
| Richard E. Buller | Option exercise | Common Stock | 1,100 | $14.83 | $16K | |
| Richard E. Buller | Open-market sale | Common Stock | 1,100 | $98.13 footnote F2 | $108K | |
| Richard E. Buller | Gift | Common Stock | 500 | $0.00 | - | |
| Richard E. Buller | Option exercise | Stock Option (right to buy) | 1,100 | $0.00 | - | |
| ||||||
| David Dalvey | Open-market sale | Common Stock | 15,000 | $100.00 footnote F2 | $1.50M | |
| ||||||
| Richard E. Buller | Option exercise | Common Stock | 3,900 | $14.83 | $58K | |
| Richard E. Buller | Open-market sale | Common Stock | 3,900 | $96.73 footnote F2 | $377K | |
| Richard E. Buller | Option exercise | Stock Option (right to buy) | 3,900 | $0.00 | - | |
| Richard E. Buller | Gift | Common Stock | 500 | $0.00 | - | |
| ||||||
| Richard Nigon | Other | Common Stock | 4,672 | $7.56 | $35K | |
| Richard Nigon | Other | Common Stock | 3,245 | $7.56 | $25K | |
| Richard Nigon | Other | Warrants (right to buy) | 4,672 | $0.00 | - | |
| Richard Nigon | Other | Warrants (right to buy) | 3,245 | $0.00 | - | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 13,976 | $56.22 | $786K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 151,524 | $56.22 | $8.52M | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 388 | $58.02 | $23K | |
| BAKER BROS. ADVISORS LP | Open-market purchase | Common Stock | 4,212 | $58.02 | $244K | |
| Brian F. Sullivan - Officer | Other | Common Stock | 104,340 | $8.05 | $840K | |
| Brian F. Sullivan - Officer | Other | Warrants (right to buy) | 104,340 | $0.00 | - | |
| Vicky Hahne - Officer | Grant or award | Stock Option (right to buy) | 80,000 | $0.00 | - | |
Item 5.02, 7.01, 9.01
Item 7.01, 8.01, 9.01
Item 7.01, 8.01, 9.01
Item 2.02, 9.01
Recent CELC Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - |
CELC insider trading FAQ
What is the latest insider trade for CELC?
Celcuity Inc. (CELC) had 6 insider filings in the last 90 days, with the most recent on 2026-10-09. The full record for CELC runs to 37 Form 4 filings, the earliest from 2024-10-25. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CELC stock?
No insider purchases of CELC were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling CELC stock?
2 insider sales of CELC were filed in the last 90 days, totaling $317.75M.
Where can I see CELC SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CELC Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Leo Furcht view on EDGAR
- - David W. Gryska view on EDGAR
- - Lance G. Laing view on EDGAR
- - Brian F. Sullivan view on EDGAR
- - Vicky Hahne view on EDGAR
- - BAKER BROS. ADVISORS LP view on EDGAR
- - Polly A. Murphy view on EDGAR
- - Richard E. Buller view on EDGAR
- - Polly A. Murphy view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where CELC's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CELC with a 7-day demo
- CELC on your watchlist
- Every CELC Form 4 filing on record
- Up to 3 months of CELC price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
